{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:22:37Z","timestamp":1792282957480,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001832","name":"Radboud Universiteit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018044","name":"Verily Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008359","name":"Maag Lever Darm Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ebiom.2026.106354","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:55:05Z","timestamp":1783630505000},"page":"106354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2965-8450","authenticated-orcid":false,"given":"Milan","family":"Beckers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bea","family":"Kuiperij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejko","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-7876","authenticated-orcid":false,"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106354_bib1","author":"Bisello"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","article-title":"DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease","volume":"13","author":"Appleton","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41467-025-56293-z","article-title":"Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment","volume":"16","author":"Bolsewig","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","article-title":"Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease","volume":"147","author":"Rutledge","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106354_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","article-title":"DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease","volume":"3","author":"Pereira","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","article-title":"Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease","volume":"12","author":"Paslawski","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib7","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","article-title":"CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease","volume":"14","author":"del Campo","year":"2023","journal-title":"Nature Communications"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106354_bib8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/mds.29835","article-title":"Increased CSF DOPA decarboxylase correlates with lower DaT-SPECT binding: analyses in biopark and PPMI cohorts","volume":"39","author":"Khosousi","year":"2024","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106354_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s43587-023-00501-2","article-title":"An emerging biomarker for dopaminergic cell loss","volume":"3","author":"Verbeek","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.ebiom.2026.106354_bib10","series-title":"Basic Neurochemistry","first-page":"283","article-title":"Chapter 14 - catecholamines","author":"Gnegy","year":"2012"},{"key":"10.1016\/j.ebiom.2026.106354_bib11","series-title":"Movement Disorders","first-page":"83","article-title":"Parkinson\u2019s disease","author":"Lieberman","year":"1986"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41531-021-00172-z","article-title":"Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase","volume":"7","author":"van Rumund","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106354_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ymgme.2006.12.001","article-title":"Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes","volume":"90","author":"Verbeek","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12883-019-1394-3","article-title":"The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease","volume":"19","author":"Bloem","year":"2019","journal-title":"BMC Neurol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106354_bib15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106354_bib16","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson's disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.20982\/tqmp.16.1.p056","article-title":"EndoS: an SPSS macro to assess endogeneity","volume":"16","author":"Daryanto","year":"2020","journal-title":"Quant Meth Psych"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00273171.2014.962683","article-title":"An index and test of linear moderated mediation","volume":"50","author":"Hayes","year":"2015","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870070103","article-title":"Core assessment program for intracerebral transplantations (CAPIT)","volume":"7","author":"Langston","year":"1992","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","article-title":"Mechanisms of peripheral levodopa resistance in Parkinson's disease","volume":"8","author":"Beckers","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106354_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1755-5949.2008.00058.x","article-title":"Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease","volume":"14","author":"Hadjiconstantinou","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.ebiom.2026.106354_bib23","article-title":"Gender differences in levodopa pharmacokinetics in levodopa-na\u00efve patients with Parkinson's disease","volume":"9","author":"Conti","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ebiom.2026.106354_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.108006","article-title":"Sex differences in the pharmacokinetics of levodopa and carbidopa in patients with Parkinson's disease","volume":"139","author":"Miyaue","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106354_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106354_bib26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ana.410250616","article-title":"Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism","volume":"25","author":"Boomsma","year":"1989","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2125.1997.00610.x","article-title":"Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics","volume":"44","author":"Dingemanse","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106354_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45953-z","article-title":"A novel pathway of levodopa metabolism by commensal bifidobacteria","volume":"13","author":"Cirstea","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106354_bib29","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106354_bib31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1021\/cn5001759","article-title":"Classics in chemical neuroscience: levodopa","volume":"5","author":"Whitfield","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106354_bib32","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/ijms22137213","article-title":"A systematic review of Parkinson's disease pharmacogenomics: is there time for translation into the clinics?","volume":"22","author":"Vuleti\u0107","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2026.106354_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.520934","article-title":"Polymorphism of the dopa-decarboxylase gene modifies the motor response to levodopa in Chinese patients with Parkinson's disease","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106354_bib34","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1080\/07391102.2023.2301517","article-title":"A computational study on structural and functional consequences of nsSNPs in human dopa decarboxylase","volume":"43","author":"Birendra Kumar","year":"2025","journal-title":"J Biomol Struct Dyn"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106354_bib35","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00259-020-05120-2","article-title":"The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update","volume":"48","author":"Boccardi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:19:32Z","timestamp":1786522772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S2352396426002379"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106354","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106354"}}